1 completed, 1 terminated. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow GSK2586184: new trials by email Literature Review of GSK2586184 trials Research Report on GSK2586184
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Dose Ranging Study to Evaluate the Safety and Efficacy of GSK2586184 in Patients With Chronic Plaque Psoriasis 100 mg GSK2586184, 200 mg GSK2586184, 400 mg GSK2586184 - Psoriasis | Phase 2 | Completed | GlaxoSmithKline | 68 | 2013-03-01 | 2017-08-03 |
| An Adaptive Phase II Study to Evaluate the Efficacy, Pharmacodynamics, Safety and Tolerability of GSK2586184 GSK2586184 50 mg, GSK2586184 100 mg, GSK2586184 200 mg - Systemic Lupus Erythematosus | Phase 2 | Terminated | GlaxoSmithKline | 51 | 2013-03-01 | 2017-04-26 |
Lupus Erythematosus, Systemic (1) · Psoriasis (1)
GlaxoSmithKline (2)
Germany (2) · Argentina (1) · Chile (1) · Czechia (1) · Estonia (1) · France (1) · Greece (1) · Hong Kong (1) · Hungary (1) · Peru (1) · Poland (1) · Romania (1) · South Africa (1) · South Korea (1) · Spain (1)